36 research outputs found
Recommended from our members
Contribution to Jesus and Justice: stories of radical Christian living
I was invited to convene a series of dialogues to form the editorial content to this book. The book contains 25 stories of faith-informed activism in the UK: from eco-justice; gender inclusion; homelessness; economics and migrant advocacy. I convened 5 zoom dialogues looking at blocks of stories, edited these films for Youtube, and then provided short 1500 word summaries which acted as commentary and discussion starters. Dialogue partners ranged from nationally accomplished theologians to MPs, and experienced activists. My contribution was to aid the public theological content and dissemination for the book.
We bring together 25 authors from across the UK, writing about their lived experience of seeking Jesus and justice in their communities. Some you will know (we have new stories from Steve Chalke, Anthony Reddie, Anji Barker and Mike Royal...) as well as others you may not have heard about yet. They speak honestly, from the heart, in accessible stories. This is not a heavy theological book trying to have the last word. It's a moving collection of 'first word' stories to encourage you. We have grouped our authors' stories around verses from the beautiful vision of Shalom in Isaiah 65:17-23. We explore eco-justice, poverty and placemaking, housing, migration, economics, education and criminal justice. We've added five dialogues from leading British theologians and experienced activists. These appear in summary at the end of every section. You can view longer 20 min recordings of these dialogues FREE on our accompanying website redletterchristians.org.uk. Whichever theme you start with, you can listen to our conversations and use them to spark discussions in your church or community. Our book will inspire you with what is possible when a Jesus-centred faith is at the heart of activism
Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial
Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials.
Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.
Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049